RC110 data is advanced and robust. If a license deal were to happen with our friends at Astex, I would expect this to drop before 2nd November or AGM.
Abbvie is a dark horse and fresh off the block so may be 3 months post ASH. Otherwise another unknown player between now and 30th June.
If extending beyond this I would not be holding my breath. Just speculation, as a deal may or may not happen, we are ‘fully funded’ for this program.
But if a deal is struck biobucks and funding can be redirected to other programs.
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-207
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.045(2.73%) |
Mkt cap ! $273.5M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.66 | $1.61 | $159.4K | 98.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5684 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |